폐 전이를 동반한 연부조직 육종(STS) - 시장 인사이트, 역학, 시장 예측(2036년)

Soft Tissue Sarcoma With Lung Metastasis Market and Epidemiology Analysis

• Metastasis is not uncommon; in fact, approximately 40% to 50% of individuals with STS will eventually develop metastatic disease. Among all possible sites, the lungs are by far the most common destination for metastases, accounting for nearly 80% of first metastatic occurrences.
• Patients who present with STS of the lower extremity, higher grade, and either leiomyosarcoma, spindle cell, or synovial cell sarcoma were more likely to present with lung metastases.
• Pulmonary metastasectomy is widely accepted as a standard treatment approach for lung metastases from STS.
• While metastatic STS carries a poorer prognosis, aggressive treatments like metastasectomy and stereotactic body radiation therapy (SBRT) can improve survival, which ranges from 26% to 30%.
• Patients with lung metastases had worse survival than patients without metastases. However, survival was better in patients with isolated lung metastases than in those with any combination of lung, bone, brain, and/or liver metastases.
• There are currently no therapies specifically approved for STS with lung metastases. While various systemic therapies are used to manage metastatic STS, none are uniquely indicated for lung metastases. Annamycin (Moleculin Biotech), Volrustomig (MEDI5752) + SBRT (Institut Claudius Regaud/AstraZeneca) is the only known drug in active clinical development targeting this specific population.
• In June 2025, Moleculin Biotech reported promising efficacy results for Annamycin from its Phase Ib/II clinical trial in patients with STS-LM. The data demonstrated encouraging anti-tumor activity in a heavily pretreated and difficult-to-treat population, supporting Annamycin's potential role as a novel systemic option for pulmonary metastatic sarcoma and reinforcing continued clinical development in this setting.

Key Factors Impacting the Soft Tissue Sarcoma With Lung Metastasis Market Growth

• Rising Incidence and Improved Detection Rates

The growing incidence of Soft Tissue Sarcoma, coupled with better diagnostic capabilities, is a major driver of market growth. Advances in imaging technologies such as high-resolution CT scans and PET imaging have significantly improved the early detection of lung metastases, enabling timely intervention and expanding the treated patient pool.

• Advancements in Targeted and Systemic Therapies

The development of novel targeted therapies, Tyrosine Kinase Inhibitors, and immunotherapies has transformed the treatment landscape for metastatic STS. These therapies offer improved survival outcomes and better tolerability compared to conventional chemotherapy, driving increased adoption and market expansion.

• Expanding Role of Precision Medicine

Growing emphasis on molecular profiling and biomarker-driven treatment selection is supporting personalized therapy approaches in STS with lung metastasis. Precision medicine is enabling optimized treatment sequencing, improved response rates, and prolonged disease control, thereby fueling market growth.

• Increasing Focus on Metastatic Disease Management

Clinical focus is shifting toward aggressive management of lung metastases through multimodal approaches, including systemic therapy, metastasectomy, and stereotactic body radiotherapy. This integrated care approach is improving patient outcomes and increasing demand for advanced therapeutic options.

• Rising R&D Investments and Clinical Trial Activity

Pharmaceutical and biotechnology companies are increasingly investing in research and development for rare and aggressive cancers such as STS. The expanding pipeline of novel agents and combination therapies targeting metastatic disease is strengthening the market outlook.

• Growing Awareness and Improved Access to Specialized Care

Enhanced awareness among clinicians and patients, along with improved access to specialized sarcoma centers, is leading to higher diagnosis and treatment rates. Multidisciplinary care models are supporting optimal disease management and contributing to sustained market growth.

• Supportive Regulatory and Orphan Drug Landscape

Favorable regulatory frameworks and orphan drug incentives are encouraging innovation in STS therapeutics. Accelerated approvals and market exclusivity benefits are attracting new entrants and supporting long-term market expansion.

• Launch of Emerging Drugs

Expected advancement of novel candidates such as Annamycin, IP-001, and a few others may modestly expand future options; however, the overall development landscape for STS-LM continues to be constrained, underscoring a significant unmet need.

DelveInsight's "Soft Tissue Sarcoma With Lung Metastasis Market Insight, Epidemiology and Market Forecast - 2036" report delivers an in-depth analysis of STS with lung metastasis epidemiology, market, and clinical development in STS with lung metastasis with lung metastasis. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the STS with lung metastasis with lung metastasis market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

The STS with lung metastasis with lung metastasis Treatment Market Report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted STS with lung metastasis with lung metastasis market size from 2022 to 2036 in 7MM. The report also covers current STS with lung metastasis with lung metastasis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Soft Tissue Sarcoma With Lung Metastasis Understanding

Soft Tissue Sarcoma With Lung Metastasis Overview and Diagnosis

Soft Tissue Sarcoma is a diverse group of rare malignant tumors that originate in the mesodermal tissues-such as fat, muscle, blood vessels, deep skin layers, tendons, and ligaments-that support and connect various parts of the body. While these tumors can occur anywhere, they most often begin in the arms or legs, but can also develop in the trunk, head and neck, internal organs, or the retroperitoneal space (the area behind the abdominal cavity). One of the major challenges in STS is its potential to spread beyond the original tumor site.

Metastasis is not uncommon; in fact, approximately 40% to 50% of individuals with STS will eventually develop metastatic disease. Among all possible sites, the lungs are by far the most common destination for metastases, accounting for nearly 80% of first metastatic occurrences. When STS spreads to the lungs, it typically signals a more advanced stage of the disease, requiring a shift in treatment goals-from curative intent to controlling disease progression, alleviating symptoms, and extending survival. STS with lung metastasis is diagnosed through a combination of imaging scans, biopsies, and sometimes blood tests. Imaging, like chest X-rays, CT scans, or MRIs, can reveal the presence of tumors in the lungs. Biopsies, where tissue samples are examined under a microscope, confirm the diagnosis and determine the specific type of sarcoma.

The STS with lung metastasis report provides an overview of STS with lung metastasis pathophysiology, and diagnostic approaches, along with a real-world scenario of a patient's journey beginning from the first symptom, the time taken for diagnosis to the entire treatment process.

Soft Tissue Sarcoma With Lung Metastasis Treatment

Pulmonary metastases are a sign of advanced disease and are always a challenge in the management of oncologic patients. The mainstay of treatment is the surgical resection of all metastatic nodules which offers a potentially curative option and a significant survival advantage. In the setting of metastatic sarcoma, lung involvement is frequent, and the disease tends to recur with a significantly higher pattern than in any other tumor type. Multiple or even extended operations are often necessary. Alongside the operative approach, medical therapy has been reported with variable results. Currently, single-agent chemotherapy or combinations are reserved for patients with chemosensitive histology or patients considered for multimodality therapy. The role of immunotherapy, instead, despite promising results, is still under investigation. Radiotherapy has been boosted in recent years, with the spread of stereotactic body radiation therapy which overwhelmed the traditional sarcomas' radioresistance.

Soft Tissue Sarcoma With Lung Metastasis Epidemiology

As the market is derived using a patient-based model, the STS with lung metastasis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of STS, Total Incident Cases of STS-LM, and Gender-specific Incident Cases of STS-LM in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2022 to 2036.

Key findings from the Soft Tissue Sarcoma With Lung Metastasis Epidemiological Analysis and Forecast

• Based on our secondary research, STS represents a meaningful oncologic burden, with approximately 14,000 new cases diagnosed annually in the US. Notably, up to 50% of these patients eventually develop lung metastases, highlighting the substantial progression risk and the clinical impact of STS-LM.
• In Germany, secondary research indicates that STS has an incidence of approximately 6.05 cases per 100,000 population, reflecting a notable disease burden and the potential progression to advanced and metastatic stages such as STS-LM.
• In Japan, secondary research indicates that STS has an incidence of approximately 3.22 cases per 100,000 population per year, reflecting a measurable but clinically significant disease burden with potential progression to advanced and metastatic stages such as STS-LM.

Soft Tissue Sarcoma with Lung Metastasis Epidemiology Segmentation in the 7MM

• Total Incident Cases of STS
• Total Incident Cases of STS-LM
• Gender-specific Incident Cases of STS-LM

Soft Tissue Sarcoma With Lung Metastasis Drug Analysis

The drug chapter segment of the STS with lung metastasis Therapeutics Market Report encloses a detailed analysis of STS with lung metastasis marketed drugs and late-stage (Phase III and Phase II) Soft Tissue Sarcoma With Lung Metastasis Pipeline Drugs. It also deep dives into the STS with lung metastasis's pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Soft Tissue Sarcoma With Lung Metastasis Emerging Drugs

• Annamycin: Moleculin Biotech

Annamycin is an investigational next-generation anthracycline developed by Moleculin, designed to overcome multidrug resistance. It incorporates lipid-based delivery to enhance tumor uptake while reducing cardiotoxicity, with development focused on aggressive and treatment-refractory cancers, including select sarcoma and hematologic malignancies. Currently in Phase I/II clinical development. In December 2020, Moleculin Biotech reported that the US Food and Drug Administration granted ODD to Annamycin for the treatment of soft tissue sarcomas.

• IP-001: Immunophotonics

IP-001 is an investigational intratumoral immunotherapy developed by Immunophotonics for soft tissue sarcoma. It employs a photothermal mechanism to induce localized tumor cell death and stimulate systemic anti-tumor immune responses, with development focused on advanced and refractory sarcoma settings. Currently in Phase I/II clinical development for non-small cell lung cancer (NSCLC) and STS, with Phase I enrollment for STS completed. In September 2023, Immunophotonics reported that the first patient was dosed in its multinational clinical trial in France, marking a key milestone in the clinical development of its investigational immunotherapy program.

Soft Tissue Sarcoma With Lung Metastasis Market Outlook

The gold standard for patients with localized STSs is surgical-wide resection with oncologic margins. In contrast, STS patients with metastatic lesions are treated by systemic chemotherapy, radiation, and possibly with resection of the primary tumor or metastatic lesions. Doxorubicin, the first-line palliative chemotherapy, is recommended as a therapeutic option for the majority of STS patients with Lung Metastases. Pulmonary metastasectomy is also a proven standard approach for the management of STS patients with LM, and some published studies have indicated that 5-year overall survival (OS) ranges from 43% to 50.9% in patients following this procedure. In addition, Matsuoka et al reported surgical resection of a primary tumor in the extremities could improve survival for metastatic STS patients. Despite efforts to improve the clinical outcome of these patients, the prognosis remains poor.

There are currently no therapies specifically approved for STS with lung metastases. While various systemic therapies are used to manage metastatic STS, none are uniquely indicated for lung metastases. Soft Tissue Sarcoma With Lung Metastasis Companies are conducting trials for this segment such as Moleculin Biotech, AstraZeneca, and others.

• In 2024, the United States accounts for the largest Soft Tissue Sarcoma With Lung Metastasis Market Size, in comparison to EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• Among the EU4 and the UK, Germany had the highest Soft Tissue Sarcoma With Lung Metastasis Market Size, while Spain had the smallest market size in 2024.

Soft Tissue Sarcoma With Lung Metastasis Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Soft Tissue Sarcoma With Lung Metastasis Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Key Soft Tissue Sarcoma With Lung Metastasis Companies

Moleculin Biotech, Institut Claudius Regaud/AstraZeneca and others.

Soft Tissue Sarcoma With Lung Metastasis Drugs Uptake

This section focuses on the uptake rate of potential Soft Tissue Sarcoma With Lung Metastasis drugs expected to be launched in the market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Soft Tissue Sarcoma With Lung Metastasis Clinical Trials Activities

The Soft Tissue Sarcoma With Lung Metastasis Therapeutics Market Report provides insights into different therapeutic candidates in Phase III and Phase II stages. It also analyzes key Soft Tissue Sarcoma With Lung Metastasis Companies involved in developing targeted therapeutics.

Soft Tissue Sarcoma with Lung Metastasis Pipeline Development Activities

The Soft Tissue Sarcoma With Lung Metastasis Therapeutics Market Report covers information on collaborations, acquisitions and mergers, licensing, and patent details for STS with lung metastasis emerging therapies.

Latest KOL Views on Soft Tissue Sarcoma With Lung Metastasis

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake along with challenges related to accessibility, including Medical/scientific writers, Professors, and Others.

DelveInsight's analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as UT Health San Antonio MD Anderson Cancer Center, University of Michigan, and Sarcoma Oncology Center etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or STS with lung metastasis market trends.

Soft Tissue Sarcoma With Lung Metastasis Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial's primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival. Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Soft Tissue Sarcoma With Lung Metastasis Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Soft Tissue Sarcoma With Lung Metastasis Market Report Scope

• The Soft Tissue Sarcoma With Lung Metastasis therapeutics market report covers a segment of key events, an executive summary, descriptive overview, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the STS with lung metastasis Treatment Market, historical and forecasted Soft Tissue Sarcoma With Lung Metastasis market size, Soft Tissue Sarcoma With Lung Metastasis market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The Soft Tissue Sarcoma With Lung Metastasis Therapeutics Market Report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM STS with lung metastasis Drugs Market.

Soft Tissue Sarcoma With Lung Metastasis Market Report Insights

• Patient-based Soft Tissue Sarcoma With Lung Metastasis Market Forecasting
• Soft Tissue Sarcoma With Lung Metastasis Therapeutics Approaches
• STS with lung metastasis Pipeline Analysis
• STS with lung metastasis Market Size and Trends
• Existing and future Soft Tissue Sarcoma With Lung Metastasis Drugs Market Opportunity

Soft Tissue Sarcoma With Lung Metastasis Market Report Key Strengths

• 11-Years Soft Tissue Sarcoma With Lung Metastasis Market Forecast
• 7MM Coverage
• STS with lung metastasis Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Soft Tissue Sarcoma With Lung Metastasis Drugs Uptake
• Key Soft Tissue Sarcoma With Lung Metastasis Market Forecast Assumptions

Soft Tissue Sarcoma With Lung Metastasis Market Report Assessment

• Current Soft Tissue Sarcoma With Lung Metastasis Treatment Practices
• Soft Tissue Sarcoma With Lung Metastasis Unmet Needs
• Soft Tissue Sarcoma With Lung Metastasis Pipeline Drugs Profiles
• Soft Tissue Sarcoma With Lung Metastasis Drugs Market Attractiveness
• Soft Tissue Sarcoma With Lung Metastasis Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions Answered in the Soft Tissue Sarcoma With Lung Metastasis Market Report

Soft Tissue Sarcoma With Lung Metastasis Market Insights

• What is the historical and forecasted STS with lung metastasis patient pool/patient burden in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Which combination treatment approaches will have a significant impact on the STS with lung metastasis drug treatment market size?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of STS with lung metastasis?
• How many companies are developing therapies for the treatment of STS with lung metastasis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?

Reasons to Buy the Soft Tissue Sarcoma With Lung Metastasis Market Report

• The Soft Tissue Sarcoma With Lung Metastasis Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the STS with lung metastasis market.
• Insights on patient burden/disease Soft Tissue Sarcoma With Lung Metastasis Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing Soft Tissue Sarcoma With Lung Metastasis Drugs Market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the Soft Tissue Sarcoma With Lung Metastasis Drugs Market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Soft Tissue Sarcoma With Lung Metastasis Drugs Market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Soft Tissue Sarcoma with Lung Metastases Executive Summary

3. Soft Tissue Sarcoma with Lung Metastases Competitive Intelligence Analysis

4. Soft Tissue Sarcoma (STS) with lung metastases: Market Overview at a Glance

• 4.1. Soft Tissue Sarcoma (STS) with lung metastases Total Market Share (%) Distribution in 2022
• 4.2. Soft Tissue Sarcoma (STS) with lung metastases Total Market Share (%) Distribution in 2036

5. Soft Tissue Sarcoma (STS) with lung metastases: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Soft Tissue Sarcoma (STS) with lung metastases Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Scenario in the 7MM (2022-2036)
• 7.4. United States Epidemiology
  • 7.4.1. Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Scenario in the United States (2022-2036)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Scenario in Germany (2022-2036)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Scenario in France (2022-2036)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Scenario in Italy (2022-2036)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Scenario in Spain (2022-2036)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Scenario in the United Kingdom (2022-2036)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Soft Tissue Sarcoma (STS) with lung metastases Epidemiology Scenario in Japan (2022-2036)

8. Soft Tissue Sarcoma with Lung Metastases Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Soft Tissue Sarcoma (STS) with lung metastases Treatment and Management
• 8.2. Soft Tissue Sarcoma (STS) with lung metastases Treatment Algorithm

9. Soft Tissue Sarcoma (STS) with lung metastases Unmet Needs

10. Key Endpoints of Soft Tissue Sarcoma (STS) with lung metastases Treatment

11. Soft Tissue Sarcoma (STS) with lung metastases Marketed Products

• 11.1. List of Soft Tissue Sarcoma (STS) with lung metastases Marketed Drugs in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

12. Soft Tissue Sarcoma (STS) with lung metastases Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

13. Soft Tissue Sarcoma (STS) with lung metastases: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Soft Tissue Sarcoma (STS) with lung metastases Market Size in 7MM
• 13.3. Soft Tissue Sarcoma (STS) with lung metastases Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Soft Tissue Sarcoma with Lung Metastases Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Soft Tissue Sarcoma (STS) with lung metastases Total Market Size in the United States
  • 15.1.2. Soft Tissue Sarcoma (STS) with lung metastases Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Soft Tissue Sarcoma (STS) with lung metastases Total Market Size in Germany
  • 15.3.2. Soft Tissue Sarcoma (STS) with lung metastases Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Soft Tissue Sarcoma (STS) with lung metastases Total Market Size in France
  • 15.4.2. Soft Tissue Sarcoma (STS) with lung metastases Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Soft Tissue Sarcoma (STS) with lung metastases Total Market Size in Italy
  • 15.5.2. Soft Tissue Sarcoma (STS) with lung metastases Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Soft Tissue Sarcoma (STS) with lung metastases Total Market Size in Spain
  • 15.6.2. Soft Tissue Sarcoma (STS) with lung metastases Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Soft Tissue Sarcoma (STS) with lung metastases Total Market Size in the United Kingdom
  • 15.7.2. Soft Tissue Sarcoma (STS) with lung metastases Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Soft Tissue Sarcoma (STS) with lung metastases Total Market Size in Japan
  • 15.8.3. Soft Tissue Sarcoma (STS) with lung metastases Market Size by Therapies in Japan

16. Soft Tissue Sarcoma with Lung Metastases Market Access and Reimbursement Overview

17. Soft Tissue Sarcoma with Lung Metastases KOL Views

18. Soft Tissue Sarcoma with Lung Metastases Market Drivers

19. Soft Tissue Sarcoma with Lung Metastases Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.